7 Best Peptides for Perimenopause

What to Know Before Choosing a Peptide for Perimenopause

Perimenopause sits at a complicated intersection in the peptide world. The transition involves erratic swings and eventual declines in multiple hormones, estrogen, progesterone, and growth hormone among them, and no peptide replaces those hormones directly. What peptides can do is work on specific downstream symptoms: metabolic disruption, libido changes, skin and tissue decline, mood instability, and the hormonal signaling pathways that influence all of the above. That narrower picture is worth understanding before looking at any individual compound.

Every compound in this guide earned its place because people use it or are actively discussing using it for perimenopause symptoms. That is the whole test. FDA-approved medications, telemedicine-prescribed compounds, and research-stage chemicals that exist only in community protocols are all eligible on equal footing. Evidence strength determines how honestly each entry describes what the research shows, not whether a compound gets a slot. You will find compounds here with completed randomized controlled trials sitting alongside compounds whose evidence is almost entirely community-reported. Both belong, and both are described as what they are.

The numbers in front of each entry reflect how prominently each compound appears in the research and in real-world perimenopause use, not a recommendation that one is better than another for you. Individual perimenopause presentations vary substantially, and the right compound depends on your specific symptom cluster, your health history, and your goals. That personalized decision lives in the MyPeptidePal app, not in this guide.

One context point worth carrying into every entry: across physician commentary, wellness clinic guidance, and real-world user reports, conventional hormone replacement therapy is consistently cited as providing greater overall symptom relief than peptides alone, because most perimenopause symptoms stem from actual hormone deficiency. Peptides are most often used as adjuncts to HRT, or as standalone support when HRT is contraindicated or declined.

1. GLP-1 Agonists (Semaglutide and Tirzepatide): For Perimenopausal Metabolic Disruption

The GLP-1 agonists are the only peptides in this guide backed by large-scale completed randomized controlled trials and FDA approval for their primary use case, which makes them the natural starting point for women whose primary perimenopause complaint is metabolic: stubborn weight gain, insulin resistance, and abdominal fat that resists diet and exercise changes.

GLP-1 stands for glucagon-like peptide-1, an incretin hormone the gut releases after meals to signal satiety to the brain and regulate glucose metabolism. Think of it as the body's built-in "fullness messenger." Semaglutide and tirzepatide are synthetic analogues of this hormone, engineered to last far longer in the body than the native molecule. Tirzepatide is a dual agonist, activating both GLP-1 receptors and GIP receptors, a second incretin that amplifies the metabolic effect. The combined result is significant appetite suppression via hypothalamic signaling, slowed gastric emptying, and improved insulin sensitivity in muscle and fat tissue.

The perimenopausal relevance is direct. Insulin sensitivity worsens during the hormonal transition, and visceral fat accumulates through mechanisms partly independent of caloric intake. The STEP 1 trial of semaglutide in adults with obesity showed approximately 15 percent average body weight reduction, one of the larger effects documented in any weight-loss intervention with completed human data. Tirzepatide has shown similar or greater effects in its own trials.

FDA approval for semaglutide covers weight management under the brand Wegovy and type 2 diabetes management under Ozempic. Tirzepatide carries FDA approval for weight management as Zepbound and for type 2 diabetes as Mounjaro. Neither is approved specifically for perimenopause, but both are frequently prescribed off-label in that context. A 2025 RAND commentary specifically addressed GLP-1 agonists in perimenopause, noting both unique potential and unique risks for this population. Community reports range from enthusiastic to neutral, with individual metabolic response varying considerably. Common side effects include nausea early in use, gastrointestinal discomfort, and appetite reduction that some users find excessive.

2. PT-141 (Bremelanotide): For Reduced Libido and Sexual Dysfunction

Reduced libido and sexual dysfunction are among the most common and least discussed symptoms of perimenopause. PT-141, sold under the brand name Vyleesi, holds the distinction of being the only compound in this guide FDA-approved specifically for sexual desire disorders in women, though the approval covers premenopausal women and perimenopausal use is off-label.

PT-141 is a cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. Its mechanism is meaningfully different from most sexual function treatments: it acts on melanocortin receptors, specifically MC3-R and MC4-R, in the central nervous system, directly modulating the brain's arousal and desire signaling. It does not work through vascular pathways. The effect is upstream, at the level of desire itself rather than the physical response.

The clinical evidence comes from the RECONNECT trials, completed randomized controlled trials in premenopausal women with hypoactive sexual desire disorder, the clinical term for chronically reduced sexual interest that causes personal distress. Those trials supported FDA approval in 2019. The data specific to perimenopausal women is more limited, and clinical use in this population is off-label. That said, the underlying mechanism is relevant to perimenopausal libido decline regardless of the formal indication, and clinicians regularly prescribe it in this context.

PT-141 is self-administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is not a daily medication. Adverse effects from the approval trials include nausea as the most common, along with flushing, headache, and transient blood pressure changes. Skin hyperpigmentation has been associated with repeated use over time. It is available by prescription through licensed physicians and telemedicine providers handling sexual health.

3. CJC-1295 and Ipamorelin: For Sleep, Metabolism, and Muscle Loss

CJC-1295 and Ipamorelin are almost always used together in perimenopause protocols, and the combination is among the most frequently mentioned by both peptide clinics and community users looking for broad metabolic and body composition support. They address a piece of the perimenopause picture that often goes underappreciated: growth hormone also declines during this transition, in parallel with sex hormones, and that decline contributes meaningfully to muscle loss, sleep disruption, and metabolic slowdown.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, the signal from the hypothalamus that tells the pituitary gland to produce and secrete growth hormone. The version used clinically includes a modification called the Drug Affinity Complex, which extends its half-life from minutes to days, allowing less frequent dosing. Ipamorelin is a selective ghrelin receptor agonist, meaning it mimics ghrelin, a hormone that triggers growth hormone release through a separate but complementary pathway. Together they work synergistically: CJC-1295 increases the amplitude of growth hormone pulses while Ipamorelin increases their frequency.

Growth hormone then signals the liver to produce IGF-1 (insulin-like growth factor 1), a protein that drives tissue repair, lean muscle synthesis, and fat mobilization. Improved growth hormone output is also linked to better deep sleep architecture, since most natural growth hormone secretion occurs during slow-wave sleep, a stage that deteriorates during perimenopause.

Completed human studies show that this combination produces sustained, dose-dependent increases in growth hormone and IGF-1 in healthy adults. Those studies were not conducted in perimenopausal populations specifically, and no perimenopause-targeted randomized controlled trial has been completed. One clinical trial involving a CJC-1295 compound was discontinued after a participant death, a safety signal that underscores the need for physician oversight and appropriate candidate selection. The theoretical relationship between elevated IGF-1 and hormone-sensitive cancers, particularly breast and ovarian, makes this combination a more carefully evaluated option for women with relevant risk factors. Use is off-label and typically conducted under physician supervision through integrative medicine or telemedicine practices.

4. BPC-157: For Joint Pain, Gut Health, and Recovery

BPC-157 is one of the most widely used peptides in biohacker and wellness communities and one of the more complicated to discuss honestly, because its regulatory status and its real-world use sit in stark tension.

It is a 15-amino acid fragment derived from a protein naturally present in human gastric juice, which is where its name, Body Protection Compound, originates. In animal studies, it promotes angiogenesis (the formation of new blood vessels, which the body uses to deliver repair resources to damaged tissue), accelerates fibroblast activity, supports collagen synthesis, reduces pro-inflammatory signaling, and appears to modulate dopamine and serotonin systems in ways that may contribute to mood effects. It also protects and repairs the gastrointestinal lining.

The perimenopausal relevance covers several symptom clusters. Joint and tendon pain are common complaints as estrogen declines, since estrogen plays a role in connective tissue integrity. Gut inflammation, which worsens for some women during the transition, sits on a meaningful gut-hormone axis. Exercise recovery slows. Some users anecdotally report improvements in brain fog, which the proposed neuroprotective effects might partly explain.

The evidence is preclinical. As of 2026, no completed human randomized controlled trial has been published for BPC-157 in any indication. A 2024 systematic review described clinical data as limited and noted that in-human safety remains uncharacterized. The FDA has classified BPC-157 as a Category 2 bulk drug substance, meaning it cannot be commercially compounded at FDA-compliant pharmacies, and has raised explicit safety concerns about its use. It also appears on the WADA prohibited list. Despite this, it circulates widely in both oral and injectable forms through grey-market channels, and user-reported experiences for joint and anti-inflammatory purposes are extensive across community forums. The pro-angiogenic mechanism raises a legitimate theoretical concern about tumor growth in women with relevant cancer risk factors. Anyone considering it should do so with full awareness of the regulatory and safety picture, and under the guidance of a physician who can evaluate individual risk.

5. GHK-Cu: For Skin Thinning, Hair Loss, and Collagen Decline

Skin thinning, loss of elasticity, and hair thinning are among the more visible symptoms of the perimenopausal transition. Estrogen plays a direct role in maintaining skin collagen density and hair follicle activity, and its decline produces measurable changes in both. GHK-Cu is the compound people most commonly reach for when those are the primary complaints.

GHK-Cu is a naturally occurring tripeptide, three amino acids (glycine, histidine, and lysine) bound to a copper ion. It is found in human plasma and saliva and declines with age. The mechanism is well characterized for topical application: GHK-Cu signals fibroblasts, the cells responsible for collagen and elastin production, to increase their output, promotes angiogenesis in skin tissue, and provides antioxidant activity through its copper component. Clinical trial data shows that topical GHK-Cu reduces wrinkle depth and volume, and the plausibility of its effects on estrogen-related skin aging is supported in dermatology literature.

For perimenopause specifically, topical formulations are where both the evidence and the safety profile are most established. Serums, creams, and scalp treatments are widely available, and the risk profile for topical use is low. Injectable GHK-Cu is used in some integrative medicine settings and combined with other compounds in biohacker protocols, but the long-term safety of injectable use is not established. Some users combine injectable NAD+ with GHK-Cu as part of broader anti-aging stacks.

GHK-Cu is not FDA-approved for any perimenopause indication, but topical cosmetic use falls under general cosmetic regulation. It is among the more conservative entry points into the perimenopause peptide space, particularly for women whose primary concern is skin and hair rather than metabolic or hormonal symptoms.

6. Kisspeptin-10: For HPG Axis Support and Hot Flash Research

Kisspeptin-10 occupies a theoretically important position in the perimenopause peptide landscape because it targets the hormonal signaling pathway that dysregulates during the transition itself. Whether the available evidence justifies its current use is a more complicated question.

The hypothalamic-pituitary-gonadal (HPG) axis is the chain of hormonal signals that governs reproductive function: the hypothalamus releases GnRH in pulses, which tells the pituitary to release LH and FSH, which in turn tell the ovaries to produce estrogen and progesterone. Think of GnRH pulses as the pacemaker of the whole reproductive system. Kisspeptin neurons in the hypothalamus, part of a cluster called KNDy neurons, are the primary drivers of that pacemaker. Kisspeptin-10 is the biologically active C-terminal fragment of kisspeptin-54 and acts on KISS1R receptors on GnRH neurons to trigger GnRH pulses.

During perimenopause, kisspeptin signaling from KNDy neurons becomes erratic, contributing to irregular GnRH pulses, irregular cycles, and through a connected pathway involving neurokinin B (another neuropeptide in the same neuron cluster), the vasomotor symptoms behind hot flashes and night sweats. The NK3 receptor antagonist fezolinetant, sold as Veozah and FDA-approved for hot flashes, works on an adjacent node of exactly this pathway, which validates the pathway's relevance even though fezolinetant is not a peptide.

Research into kisspeptin analogues for menopausal symptoms was in active Phase II trials as of 2026, with UK researchers specifically investigating Kisspeptin-10 and hot flush mechanisms. That is an emerging clinical pipeline, not completed evidence for use. As of 2026, Kisspeptin-10 is strictly a research chemical with no clinical recommendation for perimenopause and no pathway to a standard prescription. Community use exists but is limited relative to the other compounds in this guide. It is included here because the research conversation around it is real and growing, and because the mechanistic rationale is among the most direct in this list for the core hormonal disruption of perimenopause. Anyone using it is doing so well ahead of confirmed clinical evidence.

7. MOTS-c: For Mitochondrial Metabolism and Cellular Energy Decline

MOTS-c is the most biologically novel compound in this guide, and the one where the gap between theoretical interest and confirmed human evidence is widest. It earns its place because the mechanism it targets is genuinely relevant to perimenopausal metabolic decline, and because it is actively discussed and used in biohacker and longevity communities pursuing that target.

MOTS-c is a 16-amino acid peptide encoded not by the nuclear genome but by the mitochondrial genome, specifically the 12S rRNA region, which makes it a mitochondrial hormone rather than a standard peptide in the conventional sense. The body produces it naturally, but levels decline with age in a pattern that roughly parallels sex hormone decline. Researchers classify it as a mitochondrial-derived peptide, a recently characterized class of signaling molecules.

Its primary mechanism runs through AMPK, short for AMP-activated protein kinase, which functions as the cell's master metabolic sensor. When MOTS-c activates AMPK, the cascade improves glucose uptake in skeletal muscle, promotes fatty acid oxidation over storage, and enhances overall mitochondrial function and ATP production. Some research suggests it also modulates the folate and methionine cycles, affecting metabolic flux more broadly. The effect has been described as partly mimicking the metabolic adaptations triggered by exercise, which has drawn significant interest in aging research.

The perimenopausal case for MOTS-c rests on the metabolic disruption central to the transition: insulin resistance worsens, energy declines, and visceral fat accumulates. The AMPK pathway it activates is directly implicated in all three. Whether that translates to benefit in humans is largely an open question. Most data comes from animal and cell studies. Early Phase I and II investigations have begun, but no completed perimenopause-specific randomized controlled trial exists as of 2026. Real-world reports from community forums are mixed: at least one user in a perimenopause-specific community described it as the biggest letdown in her peptide experience, reporting no perceptible change in energy. That gap between the theoretical mechanism and lived experience is worth taking seriously. MOTS-c is a research compound used in biohacker circles for a compelling but unconfirmed reason.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved specifically for perimenopause?

No peptide currently holds FDA approval specifically for perimenopause as an indication. PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is used off-label in perimenopausal women. The GLP-1 agonists semaglutide and tirzepatide are FDA-approved for weight management and type 2 diabetes, and are frequently used off-label in perimenopause for metabolic symptoms. Every other compound in this guide is either research-stage or off-label for this population.

How is using a peptide for perimenopause different from hormone replacement therapy?

Hormone replacement therapy directly replaces the estrogen and progesterone that decline during perimenopause, which is why physicians and users consistently report it as producing broader symptom relief. Peptides work on downstream pathways, supporting specific functions like metabolic regulation, libido signaling, tissue repair, or growth hormone output, without replacing the hormones themselves. Most people who use peptides for perimenopause do so alongside HRT or in cases where HRT is not suitable for them, rather than as a direct substitute.

Is there a perimenopause-specific safety concern with peptides that raise IGF-1?

Yes, and it is worth understanding before considering growth hormone secretagogues. CJC-1295 and Ipamorelin raise IGF-1, which has a theoretical relationship with tumor growth in hormone-sensitive cancers including breast and ovarian. The concern is not established as a confirmed clinical risk in healthy women, but it is regularly cited by physicians as a reason for careful candidate selection and ongoing monitoring. Women with a personal or family history of hormone-sensitive cancers should discuss this specifically with a physician before considering these compounds.

Can peptides for perimenopause be obtained through a regular doctor?

It depends on the compound. PT-141 is available by prescription from any licensed physician or through telemedicine providers who handle sexual health. The GLP-1 agonists are also widely available by prescription. Growth hormone secretagogues like CJC-1295 and Ipamorelin are typically obtained through functional medicine or integrative medicine physicians, or telemedicine platforms specializing in hormone and metabolic health. Research chemicals like Kisspeptin-10 and MOTS-c are not available through any standard prescription channel and are obtained through research chemical suppliers outside the pharmaceutical system entirely.

How long does it typically take to notice effects from perimenopause peptides?

This varies significantly by compound and symptom. PT-141 is used on-demand and effects are commonly reported within about an hour of administration. GLP-1 agonists produce metabolic changes over weeks to months, with meaningful body composition changes often taking several months. Growth hormone secretagogues are typically used for extended periods, with users commonly reporting changes in sleep and body composition over six to twelve weeks of consistent use. For research compounds like MOTS-c and Kisspeptin-10, no reliable clinical timeline has been established because the human evidence base is still in early development.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for perimenopause in one place.